India offers comprehensive and affordable care for Merkel Cell Carcinoma (MCC), a rare but aggressive skin cancer, with top specialists like Dr. Ankur Bahl. Treatment in India costs between $4,000–$10,000, depending on disease stage and therapy. The same treatment can cost $40,000–$70,000 in the USA and $18,000–$28,000 in Thailand. With world-class cancer hospitals and internationally approved therapies, India delivers up to 80% cost savings with high survival outcomes.
Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine skin cancer. It arises from Merkel cells, which are located in the epidermis (top skin layer) and are involved in the sensation of touch.
Due to its rapid progression, early detection is crucial.
India’s leading oncology hospitals follow international protocols to ensure accurate diagnosis.
Diagnosis and staging are usually completed within 3–5 days of arrival in India.
Indian oncology hospitals use state-of-the-art diagnostics and therapeutic equipment to ensure optimal treatment of Merkel Cell Carcinoma:
India is rapidly becoming the top global destination for skin cancer treatment, including rare conditions like MCC. Here's why:
Dr. Ankur Bahl is one of India’s leading oncologists in the field of rare and skin cancers, including Merkel Cell Carcinoma.
Treatment Component |
Estimated Cost (USD) |
Initial Consult + Blood Work |
$300 – $500 |
Biopsy + Pathology + IHC |
$400 – $700 |
PET-CT / MRI Imaging |
$800 – $1,200 |
Surgery (Excision + SLNB) |
$1,500 – $2,500 |
Radiation Therapy (IMRT/IGRT) |
$1,200 – $2,000 |
Immunotherapy (per cycle) |
$2,000 – $5,000 |
Hospital Stay (3–5 days) |
$400 – $700 |
Total Estimated Cost |
$4,000 – $10,000 |
Note: The cost depends on stage, response to treatment, number of immunotherapy cycles, and hospital choice.
Country |
Estimated Total Cost |
India |
$4,000 – $10,000 |
Thailand |
$18,000 – $28,000 |
USA |
$40,000 – $70,000 |
India delivers equal or better clinical outcomes at one-fourth the cost compared to the US, making it an excellent choice for uninsured or self-paying patients.
Merkel Cell Carcinoma is a rare, fast-growing skin cancer that requires prompt, expert-led treatment. India offers a unique advantage with its blend of clinical excellence, cost-efficiency, and advanced technology. Foreign patients benefit from the experience of specialists like Dr. Ankur Bahl, world-class hospitals, and seamless care coordination. Whether for surgery, radiation, or immunotherapy, India provides comprehensive and compassionate oncology care that meets global standards—at just a fraction of the international cost.
Yes, when diagnosed early and treated with surgery and/or radiation, MCC has a good chance of cure. In Stage I–II, the 5-year survival rate can exceed 70%. Immunotherapy in advanced cases can lead to long-term remission.
Checkpoint inhibitors like Avelumab, Nivolumab, and Pembrolizumab have a 50–60% response rate in advanced MCC, with some patients achieving long-term disease control.
Most hospitals can begin within 3–5 days of arrival, thanks to no waitlists and pre-scheduling.
Are US/Europe-approved drugs available in India?
Yes. Many patients undergo surgery or initial treatment in India and continue immunotherapy at home. You will receive complete documentation and remote support.
Absolutely. Most major cancer centers are NABH- or JCI-accredited, ensuring global hygiene and safety standards.
Some Indian hospitals accept direct billing from international insurers or support you in claim filing. Check with your insurer in advance.